Van Berkom & Associates Inc. Reduces Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Van Berkom & Associates Inc. reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 387,998 shares of the medical research company’s stock after selling 1,836 shares during the quarter. Charles River Laboratories International makes up about 2.1% of Van Berkom & Associates Inc.’s holdings, making the stock its 26th biggest holding. Van Berkom & Associates Inc. owned about 0.76% of Charles River Laboratories International worth $71,624,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc increased its position in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares during the period. Pinnacle Bancorp Inc. boosted its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Assetmark Inc. grew its holdings in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares during the period. ORG Wealth Partners LLC bought a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $56,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $59,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Down 1.4 %

Charles River Laboratories International stock opened at $162.63 on Friday. The firm has a market cap of $8.32 billion, a price-to-earnings ratio of 20.35, a PEG ratio of 6.01 and a beta of 1.37. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $275.00. The stock has a fifty day simple moving average of $173.39 and a two-hundred day simple moving average of $188.81.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period last year, the company earned $2.46 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 10.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on CRL shares. The Goldman Sachs Group reduced their price target on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Barclays dropped their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research note on Tuesday. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, Morgan Stanley lowered their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $195.71.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).